CLAIM AMENDMENTS

36. (currently amended) A ~~pharmaceutical~~ composition comprising recombinant adenoviral vectors and a pharmaceutically acceptable carrier, wherein each recombinant adenoviral vector is deficient in one or more essential gene functions of one or more regions of the adenoviral genome selected from the group consisting of the E1, E2A, and E4 regions of the adenoviral genome, and wherein the ~~pharmaceutical~~ composition does not contain replication-competent adenoviruses.

37. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of E1.

38. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of E2A.

39. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of E4.

40. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is deficient in two or more essential gene functions.

41. (currently amended) The composition of claim 40, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E2A regions of the adenoviral genome.

42. (currently amended) The composition of claim 40, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of each of the E1 and E4 regions of the adenoviral genome.

43. (currently amended) The composition of claim 40, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of each of the E2A and E4 regions of the adenoviral genome.

44. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene function of each of three regions of the adenoviral genome.

45. (currently amended) The composition of claim 44, wherein ~~the~~ each adenoviral vector is deficient in one or more essential gene functions of each of the E1, E2A, and E4 regions of the adenoviral genome.

46. (currently amended) The composition of claim 36, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

47. (currently amended) The composition of claim 37, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

48. (currently amended) The composition of claim 38, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

49. (currently amended) The composition of claim 39, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

50. (currently amended) The composition of claim 40, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

51. (currently amended) The composition of claim 41, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping

sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

52. (currently amended) The composition of claim 42, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

53. (currently amended) The composition of claim 43, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

54. (currently amended) The composition of claim 44, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.

55. (currently amended) The composition of claim 45, wherein ~~the~~ each adenoviral vector is prepared in a cell that complements in *trans* the deficient essential gene functions of the adenoviral vector, wherein the genome of the cell line is free of overlapping sequences with the adenoviral vector that are sufficient to mediate a recombination event resulting in a replication competent adenoviral vector.